Eligibility Esophageal Squamous Cell Carcinoma NCT01822613

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Squamous cell carcinoma of esophagus
Item
histologically confirmed esophageal squamous cell carcinoma (escc)
boolean
C0279626 (UMLS CUI [1])
Prior Chemotherapy Quantity Oesophageal squamous cell carcinoma recurrent | Prior Chemotherapy Quantity Squamous cell carcinoma of esophagus metastatic
Item
no more than one prior chemotherapy regimen for recurrent or metastatic escc (for phase ii only).
boolean
C1514457 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0854769 (UMLS CUI [1,3])
C1514457 (UMLS CUI [2,1])
C1265611 (UMLS CUI [2,2])
C0279626 (UMLS CUI [2,3])
C1522484 (UMLS CUI [2,4])
Disease Progression | Therapy Platinum-Based Oesophageal squamous cell carcinoma recurrent | Therapy Platinum-Based Squamous cell carcinoma of esophagus metastatic | Disease recurrence | Chemotherapy Platinum-Based | Chemoradiotherapy Local disease
Item
progression during or after platinum-based therapy for recurrent or metastatic escc, or recurrence within 6 months of platinum-based chemotherapy or chemoradiotherapy for localized disease.
boolean
C0242656 (UMLS CUI [1])
C0087111 (UMLS CUI [2,1])
C1514162 (UMLS CUI [2,2])
C0854769 (UMLS CUI [2,3])
C0087111 (UMLS CUI [3,1])
C1514162 (UMLS CUI [3,2])
C0279626 (UMLS CUI [3,3])
C1522484 (UMLS CUI [3,4])
C0679254 (UMLS CUI [4])
C0392920 (UMLS CUI [5,1])
C1514162 (UMLS CUI [5,2])
C0436307 (UMLS CUI [6,1])
C0277565 (UMLS CUI [6,2])
Item Group
C0680251 (UMLS CUI)
PI3K Inhibitor | ERBB3 Receptor Protein-Tyrosine Kinase Antibodies | Bispecific Antibodies HER3 Targeted
Item
patients who received prior phosphoinositide-3-kinase (pi3k) inhibitor or anti-receptor tyrosine-protein kinase erbb-3 (erbb3 or her3) antibody treatment, including bi-specific antibodies with her3 as one of the targets (patients with prior exposure to pertuzumab or epidermal growth factor receptor (egfr)-targeted agents are eligible)
boolean
C1519050 (UMLS CUI [1])
C0072460 (UMLS CUI [2,1])
C0003241 (UMLS CUI [2,2])
C0206492 (UMLS CUI [3,1])
C0812265 (UMLS CUI [3,2])
C1521840 (UMLS CUI [3,3])
Tumor tissue sample Unavailable
Item
patients who do not have an archival or fresh tumor sample (or sections of it) available or readily obtainable.
boolean
C0475358 (UMLS CUI [1,1])
C0686905 (UMLS CUI [1,2])
CNS metastases
Item
patients with central nervous system (cns) metastatic involvement.
boolean
C0686377 (UMLS CUI [1])
Cancer treatment Systemic | Chemotherapy cycle | Biological treatment | Nitrosourea | Mitomycin
Item
patients who have received prior systemic anti-cancer treatment, such as cyclical chemotherapy or biological therapy within a period of time that is shorter than the cycle length used for that treatment (e.g. 6 weeks for nitrosourea, mitomycin-c) prior to starting study treatment.
boolean
C0920425 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])
C1302181 (UMLS CUI [2])
C1531518 (UMLS CUI [3])
C0028210 (UMLS CUI [4])
C0002475 (UMLS CUI [5])
Therapeutic radiology procedure Recent | Side effects Recovery Lacking | Bone Marrow Percentage irradiated
Item
patients who have received definitive radiotherapy ≤ 4 weeks prior to starting study drug, who have not recovered from side effects of such therapy and/or from whom ≥ 30% of the bone marrow was irradiated.
boolean
C1522449 (UMLS CUI [1,1])
C0332185 (UMLS CUI [1,2])
C0879626 (UMLS CUI [2,1])
C2004454 (UMLS CUI [2,2])
C0332268 (UMLS CUI [2,3])
C0005953 (UMLS CUI [3,1])
C0439165 (UMLS CUI [3,2])
C1522449 (UMLS CUI [3,3])
Eligibility Criteria Study Protocol
Item
other protocol-defined inclusion/exclusion criteria may apply.
boolean
C1516637 (UMLS CUI [1,1])
C2348563 (UMLS CUI [1,2])

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial